Holen Sie sich die Stockscreener-App
70.63
0.51%
-0.36
Handel nachbörslich:
71.52
0.89
+1.26%
Schlusskurs vom Vortag:
$70.99
Offen:
$70.675
24-Stunden-Volumen:
1.88M
Relative Volume:
0.78
Marktkapitalisierung:
$13.61B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-29.31
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
+7.68%
1M Leistung:
+30.17%
6M Leistung:
+111.85%
1J Leistung:
+159.76%
1-Tages-Spanne:
$69.53
$71.65
1-Wochen-Bereich:
$64.41
$71.65
52-Wochen-Spanne:
$25.34
$71.65
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
70.63 | 13.68B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio to Participate in December Investor Conferences - The Manila Times
BridgeBio (Nasdaq: BBIO) to present at Piper Sandler and EvercoreISI conferences - Stock Titan
BridgeBio Pharma Insider Sold Shares Worth $1,722,224, According to a Recent SEC Filing - MarketScreener
BridgeBio Pharma CEO Kumar Neil sells $1.7m in shares By Investing.com - Investing.com Nigeria
BridgeBio Pharma CEO Kumar Neil sells $1.7m in shares - Investing.com
Biotech Stock Could Turn 4-Year Peak Into Records - Finviz
BridgeBio Pharma stock hits 52-week high at 69.69 USD By Investing.com - Investing.com Australia
BridgeBio Pharma stock hits 52-week high at 69.69 USD - Investing.com India
BridgeBio Pharma: Set For New Commercial Launches After Trial Successes - Seeking Alpha
BridgeBio Pharma (BBIO) Price Target Increased by 16.55% to 82.90 - MSN
BridgeBio Pharma Independent Director Wen-Chaun Lo Sells 62% Of Holding - simplywall.st
Will BridgeBio Pharma Inc. stock split attract more investors2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
Will BridgeBio Pharma Inc. (2CL) stock outperform value peersWall Street Watch & Low Drawdown Investment Ideas - newser.com
Will BridgeBio Pharma Inc. stock gain from lower inflationJuly 2025 Short Interest & Short-Term High Return Strategies - newser.com
Why BridgeBio Pharma Inc. (2CL) stock stays resilientMarket Volume Report & Weekly High Momentum Picks - newser.com
Can BridgeBio Pharma Inc. (2CL) stock ride next bull market cycle2025 Fundamental Recap & Risk Controlled Stock Alerts - newser.com
How BridgeBio Pharma Inc. stock performs in stagflationShare Buyback & Free Daily Entry Point Trade Alerts - newser.com
Bridgebio Pharma Insider Sold Shares Worth $6,319,662, According to a Recent SEC Filing - MarketScreener
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma (Nasdaq: BBIO) approves 34,199 inducement RSUs for 12 new employees - Stock Titan
Analyzing BridgeBio Pharma Inc. with risk reward ratio chartsMarket Rally & Verified Chart Pattern Signals - newser.com
How dovish Fed policy supports BridgeBio Pharma Inc. (2CL) stockWeekly Trend Summary & Technical Entry and Exit Alerts - newser.com
BridgeBio Pharma Insider Sold Shares Worth $1,125,404, According to a Recent SEC Filing - MarketScreener
BridgeBio Pharma (BBIO) president Trimarchi sells $1.12 million in stock By Investing.com - Investing.com South Africa
BridgeBio Pharma (BBIO) president Trimarchi sells $1.12 million in stock - Investing.com India
What moving averages say about BridgeBio Pharma Inc.Weekly Trade Report & AI Enhanced Trade Execution Alerts - newser.com
BridgeBio Pharma (BIT:1BBIO) Price Target Increased by 19.13% to 72.40 - Nasdaq
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):